NCT03854032 2025-06-06
Nivolumab and BMS986205 in Treating Patients With Stage II-IV Squamous Cell Cancer of the Head and Neck
Thomas Jefferson University
Phase 2 Active not recruiting
Clinical Trials
6 trialsNCT02935634 2023-06-09
FRACTION-GC
Bristol-Myers Squibb
Phase 2 Completed
NCT03519256 2023-06-01
CheckMate 9UT
Bristol-Myers Squibb
Phase 2 Terminated
NCT02996110 2022-12-19
FRACTION-RCC
Bristol-Myers Squibb
Phase 2 Completed
NCT02750514 2021-03-22
FRACTION-Lung
Bristol-Myers Squibb
Phase 2 Terminated
NCT04007588 2020-02-05
A Phase II Trial of Neoadjuvant Treatment With PD-1 Inhibition (Nivolumab) With or Without IDO Inhibition (BMS-986205) and With or Without CTLA-4 Inhibition (Ipilimumab) in Resectable Stage III or IV Melanoma
Dana-Farber Cancer Institute
Phase 2 Withdrawn